Paul Hudson, Sanofi CEO (Marlene Awaad/Bloomberg via Getty Images)
Sanofi flunks Parkinson's Phase II, axes handful of mid-stage programs in Q4 earnings
Biogen isn’t the only one hitting roadblocks in Parkinson’s.
Two days after the big biotech revealed in year-end earnings that they cut a Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
